

**UNITED STATES DEPARTMENT OF COMMERCE****Patent and Trademark Office**Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

Mv

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

09/051,013 10/09/98 BESTOR

T 48075-B-PCT

HM12/0310

EXAMINER

JOHN P WHITE  
COOPER & DUNHAM  
1185 AVENUE OF THE AMERICAS  
NEW YORK NY 10036

KERR, J

ART UNIT	PAPER NUMBER
----------	--------------

1633

DATE MAILED: 03/10/00 \$

**Please find below and/or attached an Office communication concerning this application or proceeding.****Commissioner of Patents and Trademarks**

<b>Office Action Summary</b>	Application No. <b>09/051,013</b>	Applicant(s) <b>Timothy H. Bestor</b>
	Examiner <b>Janet M. Kerr</b>	Group Art Unit <b>1633</b>

Responsive to communication(s) filed on Aug 12, 1998

This action is **FINAL**.

Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

A shortened statutory period for response to this action is set to expire one month(s), or thirty days, whichever is longer, from the mailing date of this communication. Failure to respond within the period for response will cause the application to become abandoned. (35 U.S.C. § 133). Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

#### Disposition of Claims

Claim(s) 1-47 is/are pending in the application.

Of the above, claim(s) \_\_\_\_\_ is/are withdrawn from consideration.

Claim(s) \_\_\_\_\_ is/are allowed.

Claim(s) \_\_\_\_\_ is/are rejected.

Claim(s) \_\_\_\_\_ is/are objected to.

Claims 1-47 are subject to restriction or election requirement.

#### Application Papers

See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948.

The drawing(s) filed on \_\_\_\_\_ is/are objected to by the Examiner.

The proposed drawing correction, filed on \_\_\_\_\_ is  approved  disapproved.

The specification is objected to by the Examiner.

The oath or declaration is objected to by the Examiner.

#### Priority under 35 U.S.C. § 119

Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).

All  Some\*  None of the CERTIFIED copies of the priority documents have been

received.

received in Application No. (Series Code/Serial Number) \_\_\_\_\_.

received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

\*Certified copies not received: \_\_\_\_\_

Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

#### Attachment(s)

Notice of References Cited, PTO-892

Information Disclosure Statement(s), PTO-1449, Paper No(s). \_\_\_\_\_

Interview Summary, PTO-413

Notice of Draftsperson's Patent Drawing Review, PTO-948

Notice of Informal Patent Application, PTO-152

--- SEE OFFICE ACTION ON THE FOLLOWING PAGES ---

***Election/Restriction***

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in response to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-46, drawn to chimeric proteins, vectors encoding the chimeric proteins, and a method of using the chimeric proteins.

Group II, claim(s) 47, drawn to transgenic non-human mammals.

The inventions listed as Groups I and II do not relate to a single general inventive concept under PCT Rule 13.1 because, 37 CFR 1.475(b) does not provide for multiple independent products. The transgenic non-human mammals of Group II is an independent product from the chimeric proteins and vectors encoding the chimeric proteins of Group I. Since the products of Groups I and II are independent, a holding of lack of unity is proper.

This application contains claims directed to more than one species of the generic inventions. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows:

A. Chimeric proteins comprising:

- (a) a zinc three-finger DNA binding polypeptide linked to a CpG-specific DNA methyltransferase polypeptide,
- (b) a mutated Lex A binding polypeptide linked to a cytosine methyltransferase polypeptide,

(c) at least a portion of a mutated *M. SssI* DNA methyltransferase protein or at least a portion of a mutated mammalian DNA methyltransferase protein.

The species do not relate to a single general inventive concept under PCT Rule 13.1 because, 37 CFR 1.475(b) does not provide for multiple independent products. The chimeric proteins comprise distinct amino acid sequences and are thus independent products, therefore, a holding of lack of unity is proper.

B. Target genes associated with:

- (a) cancer,
- (b) a central nervous system disorder,
- (c) a blood disorder,
- (d) a metabolic disorder,
- (e) a cardiovascular disorder,
- (f) an autoimmune disorder, and
- (g) an inflammatory disorder.

The species do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the claimed disorders have different etiologies, therefore, the target genes associated with each disorder are likely to be distinct, and would require targeting to different cell populations and different tissues. Thus, different technical considerations would be necessary for targeting diseases of different etiologies which affect different cell types.

C. Target genes wherein the target gene is:

- (a) endogenous, or

(b) foreign.

The species do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the claim-designated endogenous and foreign target genes have distinct structures based on their origin, including the promoter regions to be targeted. Thus, determination of the ability to methylate an endogenous target gene and a foreign target gene (such as viral or retroviral target genes), and the methods for delivering the chimeric protein to chromosomal (as in the case of endogenous target genes) versus extrachromosomal (which can be the case for viral genes) genetic material would require different technical considerations.

D. Multicellular organisms including:

- (a) plants, and
- (b) animals.

The species do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the methods for inhibiting expression of a target gene in a multicellular organism such as an animal would require different technical considerations for delivery of the chimeric protein compared to methods for inhibiting expression of a target gene in a multicellular organism such as a plant in view of the anatomical and physiological distinctions between plants and animals.

Applicant is required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument

that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(I).

#### *Sequence Compliance*

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

While the sequences disclosed do not comply with the sequence rules cited above, the sequence is deemed non-essential to the examination of this application at this time because the application is being examined for restriction purposes only. Applicant is therefore given the entire period for responding to this action to comply with the sequence rules. FAILURE TO COMPLY

FULLY WITH THE SEQUENCE RULES WITHIN THE RESPONSE PERIOD SET FOR THIS OFFICE ACTION WILL BE CONSIDERED AN INCOMPLETE RESPONSE.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Janet M. Kerr whose telephone number is (703) 305-4055. Should the examiner be unavailable, inquiries should be directed to John LeGuyader, Supervisory Primary Examiner of Art Unit 1633, at (703) 308-0447. Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The CM1 Fax Center number is (703) 305-7401. Any inquiry of a general nature or relating to the status of this application should be directed to the Group 1600 receptionist whose telephone number is (703) 308-0196.

The Group and/or Art Unit location of your application in the PTO has changed. To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Group Art Unit 1633.

  
Janet M. Kerr, Ph.D.  
Patent Examiner  
Group 1600

  
DEBORAH J. CLARK  
PATENT EXAMINER

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- 7. Other: the topology of the sequence was not reported.

**Applicant Must Provide:**

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**